An Endpoint Is Not a Biomarker, and That Difference Can Kill a Drug : Rethinking Endpoints in the Age of AI (Part 2)

In the previous chapter, we looked at a case that generated considerable noise in the community: the supposed “approval of an AI-based endpoint.”